The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu, MD, MD Anderson Cancer Center, Houston, TX, provides an overview of the results of ZUMA-12 (NCT03761056), a Phase II trial evaluating axicabtagene ciloleucel (axi-cel) as first-line therapy in high-risk large B-cell lymphoma. The primary endpoint in efficacy-evaluable patients was met, with a 78% complete response rate and an 89% objective response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
